This transgene consists of the human alpha-synuclein cDNA encoding a mutated protein with an Ala53Thr mutation under the control of the tetracycline responsive promoter. The mutant alpha-synuclein is expressed only in the presence of the tetracycline transactivator (tTA), expressed from a second transgene; administration of doxycycline inhibits tTA binding to tetO, thus suppressing alpha-synuclein expression.